Cirrhosis is the severe scarring or fibrosis of the liver. It happens in the late stage of liver disease and other conditions that involve liver damage. The scarring that occurs with cirrhosis is ...
Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, prioritizing early intervention and improved patient outcomes. Innovations ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Cellular senescence, where cells permanently stop dividing, plays a complex role in liver health. In a recent review article, ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback